|
 |
|
|||||||
|
|||||||||
© 2002 by the American Diabetes Association, Inc.
MEDICA 16 Inhibits Hepatic Acetyl-CoA Carboxylase and Reduces Plasma Triacylglycerol Levels in Insulin-Resistant JCR
LA-cp Rats
1 Cardiovascular Research Group, Faculty of Medicine, the University of Alberta, Edmonton, Canada
2 Muttart Diabetes Research and Training Center, Faculty of Medicine, the University of Alberta, Edmonton, Canada
3 Department of Pediatrics, Faculty of Medicine, the University of Alberta, Edmonton, Canada
4 Department of Surgery, Faculty of Medicine, the University of Alberta, Edmonton, Canada
5 Department of Human Nutrition and Metabolism, Hadassah Medical School, Jerusalem, Israel
Intracellular triacylglycerol (TG) content of liver and skeletal muscle contributes to insulin resistance, and a significant correlation exists between TG content and the development of insulin resistance. Because acetyl-CoA carboxylase (ACC) is the rate-limiting enzyme for liver fatty acid biosynthesis and a key regulator of muscle fatty acid oxidation, we examined whether ACC plays a role in the accumulation of intracellular TG. We also determined the potential role of 5'-AMP-activated protein kinase (AMPK) in this process, since it can phosphorylate and inhibit ACC activity in both liver and muscle. TG content, ACC, and AMPK were examined in the liver and skeletal muscle of insulin-resistant JCR:LA-cp rats during the time frame when insulin resistance develops. At 12 weeks of age, there was a threefold elevation in liver TG content and a sevenfold elevation in skeletal muscle TG content. Hepatic ACC activity was significantly elevated in 12-week-old JCR:LA-cp rats compared with lean age-matched controls (8.75 ± 0.53 vs. 3.30 ± 0.18 nmol · min-1 · mg-1, respectively), even though AMPK activity was also increased. The observed increase in hepatic ACC activity was accompanied by a 300% increase in ACC protein expression. There were no significant differences in ACC activity, ACC protein expression, or AMPK activity in the skeletal muscle of the 12-week JCR:LA-cp rats. Treatment of 12-week JCR:LA-cp rats with MEDICA 16 (an ATP-citrate lyase inhibitor) resulted in a decrease in hepatic ACC and AMPK activities, but had no effect on skeletal muscle ACC and AMPK. Our data suggest that alterations in ACC or AMPK activity in muscle do not contribute to the development of insulin resistance. However, increased liver ACC activity in the JCR:LA-cp rat appears to contribute to the development of lipid abnormalities, although this increase does not appear to occur secondary to a decrease in AMPK activity.
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Deng, S. Shan, P.-P. Li, Z.-F. Shen, X.-P. Lu, J. Cheng, and Z.-Q. Ning Peroxisome Proliferator-Activated Receptor-{gamma} Transcriptionally Up-Regulates Hormone-Sensitive Lipase via the Involvement of Specificity Protein-1 Endocrinology, February 1, 2006; 147(2): 875 - 884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Atkinson, R. Kozak, S. E. Kelly, A. Onay-Besikci, J. C. Russell, and G. D. Lopaschuk Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E923 - E930. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |